Institute of Cancer and Genomic Sciences Using fundamental research and the power of genomics to develop better therapies in cancer and other complex diseases.
News TREATWolfram clinical trial to unlock a potential treatment for a rare disease Birmingham is making a real-world impact on rare diseases, with a comprehensive multi-facility network for research helping to find new treatments for patients like those with Wolfram syndrome.
News Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse
News Cancer Research UK Clinical Trials Unit: Celebrating 40 Years of Funding From Cancer Research UK
QS World University Subject Rankings released for 2023 University of Birmingham rises 30 places to be joint 62nd in the world for Life Sciences and Medicine.
21 March 2024 Birmingham Professor Gary Middleton appointed as ECMC Network Lead Professor Gary Middleton, Professor of Oncology, will be at the forefront of pioneering cancer research as ECMC Network Lead.
15 February 2024 Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse New study provides clues to why leukaemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatment.
08 February 2024 Pioneering test to detect bladder cancer based on DNA Using urinary DNA to detect circulating tumour DNA in bladder cancer patients
02 February 2024 Cancer Research UK Clinical Trials Unit: Celebrating 40 Years of Funding From Cancer Research UK To mark four decades of funding, the Birmingham Cancer Research UK Clinical Trials Unit (CRCTU) held a special celebratory event in January.
09 January 2024 Combining anti-tumour drugs with chemo may improve rare children’s cancer outcomes Phase 2 trial found adding Bevacizumab to different chemotherapy drugs led to more patients’ tumours shrinking, which has helped to change routine UK treatment.
20 December 2023 Finding and targeting a tumour’s sweet spot to eradicate aggressive form of leukemia Screening research found that removal of RUNX1 transcription factor and target gene could lead to network collapse and cancer cell death